Kymera Therapeutics filed patents disclosing STAT6 inhibitors as small‑molecule therapeutics with indications spanning cancer, inflammatory and metabolic diseases. The disclosure outlines chemical series and claimed utility in modulating STAT6‑dependent transcriptional programs. Kymera’s patenting activity signals internal expansion beyond protein degradation platforms into direct small‑molecule pathway modulation, positioning STAT6 as a node for immune and fibrotic disease programs. For readers: STAT6 is a transcription factor downstream of IL‑4/IL‑13 signaling implicated in type‑2 immunity and fibrosis; small‑molecule inhibition represents a conventional pharmacologic approach complementary to Kymera’s degradation tech.